Skip to main content Accessibility help
  • Print publication year: 2016
  • Online publication date: March 2016

3 - Radiation therapy for gliomas

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

The Duke Glioma Handbook
  • Online ISBN: 9781107588721
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to *
1.Despeignes, V. Observation concernant un cas de cancer de l’estomac traité par les rayons Roentgen. Lyon Med, 1896;82:428–30; 503.
2.Freund, L. Ein mit Roentgen-Strahlen Behandeller Fall von Naevus pigmentosus pilferus. Wien Med Wschr, 1897;47:428–34.
3.Kogelnik, HD. Inauguration of radiotherapy as a new scientific speciality by Leopold Freund 100 years ago. Radiother Oncol, 1997;42(3):203–11.
4.Halperin, EC, Wazer, DE, Perez, CA. The discipline of radiation oncology. In: Halperin, EC, Wazer, DE, Paerez, CA, Brady, LW, eds. Principle and Practice of Radiation Oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013, pp. 260.
5.Coutard, H. Principles of X-ray therapy of malignant disease. Lancet, 1934;2:18.
6.Fowler, JF. Fractionation and therapeutic gain. In: Steele, GE, Adams, GE, Peckham, MT, eds. Biological Basis of Radiotherapy. Amsterdam: Elsevier Science; 1983, pp. 181–94.
7.American Society for Radiation Oncology. Radiation Therapy for Cancer. Fairfax, VA: ASTRO; 2013.
8.McBride, WH, Withers, HR. Biologic basis of radiation therapy. In: Halperin, EC, Wazer, DE, Perez, CA, Brady, LW, eds. Principles and Practice of Radiation Oncology, 6th ed. Philadelphia, PA: Wolters Kluwer; 2013, pp. 6188.
9.Barnett, GH, Linskey, ME, Adler, JR, Cozzens, JW, Friedman, WA, Heilbrun, MP, et al. Stereotactic radiosurgery – an organized neurosurgery-sanctioned definition. J Neurosurg, 2007;106(1):15.
10.Soldberg, TD, Balter, JM, Benedict, SH, Fraass, BA, Kavanagh, B, Miyamoto, C, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Practical Radiat Oncol, 2012;2:29.
11.Klein, EE, Hanley, J, Bayouth, J, Yin, FF, Simon, W, Dresser, S, et al. Task Group 142 report: quality assurance of medical accelerators. Med Phys, 2009;36(9):4197–212.
12.Benedict, SH, Yenice, KM, Followill, D, Galvin, JM, Hinson, W, Kavanagh, B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys, 2010;37(8):4078–101.
13.Bissonnette, JP, Balter, PA, Dong, L, Langen, KM, Lovelock, DM, Miften, M, et al. Quality assurance for image-guided radiation therapy utilizing CT-based technologies: a report of the AAPM TG-179. Med Phys, 2012;39(4):1946–63.
14.Walker, MD, Alexander, E, Jr., Hunt, WE, MacCarty, CS, Mahaley, MS, Jr., Mealey, J, Jr., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 1978;49(3):333–43.
15.Walker, MD, Green, SB, Byar, DP, Alexander, E, Jr., Batzdorf, U, Brooks, WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 1980;303(23):1323–9.
16.Laperriere, N, Zuraw, L, Cairncross, G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol, 2002;64(3):259–73.
17.Walker, MD, Strike, TA, Sheline, GE. An analysis of dose–effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys, 1979;5(10):1725–31.
18.Bleehen, NM, Stenning, SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer, 1991;64(4):769–74.
19.Chang, CH, Horton, J, Schoenfeld, D, Salazer, O, Perez-Tamayo, R, Kramer, S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer, 1983;52(6):9971007.
20.Nelson, DF, Curran, WJ, Jr., Scott, C, Nelson, JS, Weinstein, AS, Ahmad, K, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma – possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys, 1993;25(2):193207.
21.Laperriere, NJ, Leung, PM, McKenzie, S, Milosevic, M, Wong, S, Glen, J, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys, 1998;41(5):1005–11.
22.Selker, RG, Shapiro, WR, Burger, P, Blackwood, MS, Arena, VC, Gilder, JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery, 2002;51(2):343–55; discussion 55–7.
23.Souhami, L, Seiferheld, W, Brachman, D, Podgorsak, EB, Werner-Wasik, M, Lustig, R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys, 2004;60(3):853–60.
24.Minniti, G, Lanzetta, G, Scaringi, C, Caporello, P, Salvati, M, Arcella, A, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys, 2012;83(1):93–9.
25.Hochberg, FH, Pruitt, A. Assumptions in the radiotherapy of glioblastoma. Neurology, 1980;30(9):907–11.
26.Shapiro, WR, Young, DF. Treatment of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol, 1976;33(7):494–50.
27.Wallner, KE, Galicich, JH, Krol, G, Arbit, E, Malkin, MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys, 1989;16(6):1405–9.
28.Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005;352:987–96.
29.van den Bent, MJ, Afra, D, de Witte, O, Ben Hassel, M, Schraub, S, Hoang-Xuan, K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 2005;366(9490):985–90.
30.Karim, AB, Maat, B, Hatlevoll, R, Menten, J, Rutten, EH, Thomas, DG, et al. A randomized trial on dose–response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys, 1996;36(3):549–56.
31.Shaw, E, Arusell, R, Scheithauer, B, O’Fallon, J, O’Neill, B, Dinapoli, R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol, 2002;20(9):2267–76.
32.Brown, PD, Buckner, JC, O’Fallon, JR, Iturria, NL, Brown, CA, O’Neill, BP, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol, 2003;21(13):2519–24.
33.Shaw, EG, Wang, M, Coons, SW, Brachman, DG, Buckner, JC, Stelzer, KJ, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol, 2012;30(25):3065–70.
34.Cairncross, G, Wang, M, Shaw, E, Jenkins, R, Brachman, D, Buckner, J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol, 2013;31(3):337–43.
35.Mehta, MP, Won, E, Shaw, EG, Buckner, J, Gilbert, MR, Barger, GR, et al. Mature survival data from RTOG 9802: a phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) for adult patients with high-risk low-grade glioma (LGG). Int J Radiat Oncol Biol Phys, 2014;90(1):S378.
36.Chamberlain, MC. Does RTOG 9802 change practice with respect to newly diagnosed low-grade glioma? J Clin Oncol, 2013;31(5):652–3.
37.Cohen, MH, Shen, YL, Keegan, P, Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist, 2009;14(11):1131–8.
38.Kreisl, TN, Kim, L, Moore, K, Duic, P, Royce, C, Stroud, I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol, 2009;27(5):740–5.
39.Vredenburgh, JJ, Desjardins, A, Herndon, JE, 2nd, Dowell, JM, Reardon, DA, Quinn, JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 2007;13(4):1253–9.
40.Fogh, SE, Andrews, DW, Glass, J, Curran, W, Glass, C, Champ, C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol, 2010;28(18):3048–53.
41.Cabrera, HN, Almeida, AN, Silva, CC, Fonoff, ET, Martin, MG, Leite, C da C, et al. Use of intraoperative MRI for resection of gliomas. Arq Neuro-psiquiatr, 2011;69(6):949–53.
42.Cuneo, KC, Vredenburgh, JJ, Sampson, JH, Reardon, DA, Desjardins, A, Peters, KB, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys, 2012;82(5):2018–24.
43.Gutin, PH, Iwamoto, FM, Beal, K, Mohile, NA, Karimi, S, Hou, BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys, 2009;75(1):156–63.
44.Lee, DY, Chunta, JL, Park, SS, Huang, J, Martinez, AA, Grills, IS, et al. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2013;86(5):978–85.
45.Shaw, E, Scott, C, Souhami, L, Dinapoli, R, Kline, R, Loeffler, J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys, 2000;47(2):291–8.
46.Balagamwala, EH, Chao, ST, Suh, JH. Principles of radiobiology of stereotactic radiosurgery and clinical applications in the central nervous system. Technol Cancer Res Treat, 2012;11(1):313.
47.Kirkpatrick, JP, Meyer, JJ, Marks, LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol, 2008;18(4):240–3.
48.Kirkpatrick, JP, Brenner, DJ, Orton, CG. Point/counterpoint. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Med Phys, 2009;36(8):3381–4.
49.Cho, KH, Hall, WA, Gerbi, BJ, Higgins, PD, McGuire, WA, Clark, HB. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys, 1999;45(5):1133–41.
50.Hall, WA, Djalilian, HR, Sperduto, PW, Cho, KH, Gerbi, BJ, Gibbons, JP, et al. Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol, 1995;13(7):1642–8.
51.Kong, DS, Lee, JI, Park, K, Kim, JH, Lim, DH, Nam, DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer, 2008;112(9):2046–51.
52.Shrieve, DC, Alexander, E, 3rd, Wen, PY, Fine, HA, Kooy, HM, Black, PM, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery, 1995;36(2):275–82; discussion 82–4.
53.Moeller, BJ, Cao, Y, Li, CY, Dewhirst, MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell, 2004;5(5):429–41.
54.Moeller, BJ, Dewhirst, MW. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle, 2004;3(9):1107–10.
55.Moeller, BJ, Dreher, MR, Rabbani, ZN, Schroeder, T, Cao, Y, Li, CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 2005;8(2):99110.
56.Boothe, D, Young, R, Yamada, Y, Prager, A, Chan, T, Beal, K. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-Oncology, 2013;15(9):1257–63.
57.Levin, VA, Bidaut, L, Hou, P, Kumar, AJ, Wefel, JS, Bekele, BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys, 2011;79(5):1487–95.
58.Torcuator, R, Zuniga, R, Mohan, YS, Rock, J, Doyle, T, Anderson, J, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neuro-Oncol, 2009;94(1):63–8.
59.Cabrera, AR, Cuneo, KC, Desjardins, A, Sampson, JH, McSherry, F, Herndon, JE, 2nd, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys, 2013;86(5):873–9.
60.Hundsberger, T, Brugge, D, Putora, PM, Weder, P, Weber, J, Plasswilm, L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neuro-Oncol, 2013;112(1):133–9.
61.Park, KJ, Kano, H, Iyer, A, Liu, X, Niranjan, A, Flickinger, JC, et al. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neuro-Oncol, 2012;107(2):323–33.
62.Torcuator, RG, Thind, R, Patel, M, Mohan, YS, Anderson, J, Doyle, T, et al. The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neuro-Oncol, 2010;97(3):401–7.
63.Shapiro, LQ, Beal, K, Goenka, A, Karimi, S, Iwamoto, FM, Yamada, Y, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys, 2013;85(3):636–42.
64.Patel, M, Siddiqui, F, Jin, JY, Mikkelsen, T, Rosenblum, M, Movsas, B, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neuro-Oncol, 2009;92(2):185–91.
65.Niyazi, M, Ganswindt, U, Schwarz, SB, Kreth, FW, Tonn, JC, Geisler, J, et al. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys, 2012;82(1):6776.
66.McKenzie, JT, Guarnaschelli, JN, Vagal, AS, Warnick, RE, Breneman, JC. Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas. J Neuro-Oncol, 2013;113(3):403–9.
67.Douw, L, Klein, M, Fagel, SS, van den Heuvel, J, Taphoorn, MJ, Aaronson, NK, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol, 2009;8(9):810–18.
68.Mayo, C, Martel, MK, Marks, LB, Flickinger, J, Nam, J, Kirkpatrick, J. Radiation dose–volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys, 2010;76(3 Suppl):S2835.
69.Hall, EJ, Giaccia, AJ. Radiobiology for the Radiologist, 7th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012, pp. ix, 546.
70.Lawrence, YR, Li, XA, el Naqa, I, Hahn, CA, Marks, LB, Merchant, TE, et al. Radiation dose–volume effects in the brain. Int J Radiat Oncol Biol Phys, 2010;76(3 Suppl):S207.
71.Kirkpatrick, JP, Marks, LB, Mayo, C, Lawrence, YR, Bhandare, N, Ryu, S. Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. J Radiosurg SBRT, 2011;1(2):95107.
72.Mayo, C, Yorke, E, Merchant, TE. Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys, 2010;76(3 Suppl):S3641.
73.Merchant, TE, Chitti, RM, Li, C, Xiong, X, Sanford, RA, Khan, RB. Factors associated with neurological recovery of brainstem function following postoperative conformal radiation therapy for infratentorial ependymoma. Int J Radiat Oncol Biol Phys, 2010;76(2):496503.
74.Foote, KD, Friedman, WA, Buatti, JM, Meeks, SL, Bova, FJ, Kubilis, PS. Analysis of risk factors associated with radiosurgery for vestibular schwannoma. J Neurosurg, 2001;95(3):440–9.
75.Kondziolka, D, Lunsford, LD, McLaughlin, MR, Flickinger, JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med, 1998;339(20):1426–33.
76.Bhandare, N, Jackson, A, Eisbruch, A, Pan, CC, Flickinger, JC, Antonelli, P, et al. Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys, 2010;76(3 Suppl):S507.
77.Chen, WC, Jackson, A, Budnick, AS, Pfister, DG, Kraus, DH, Hunt, MA, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer, 2006;106(4):820–9.
78.Pan, CC, Eisbruch, A, Lee, JS, Snorrason, RM, Ten Haken, RK, Kileny, PR. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys, 2005;61(5):1393–402.
79.Honore, HB, Bentzen, SM, Moller, K, Grau, C. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol, 2002;65(1):916.
80.Kwong, DL, Wei, WI, Sham, JS, Ho, WK, Yuen, PW, Chua, DT, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys, 1996;36(2):281–9.
81.Curran, WJ, Jr., Scott, CB, Horton, J, Nelson, JS, Weinstein, AS, Fischbach, AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 1993;85(9):704–10.
82.Li, J, Wang, M, Won, M, Shaw, EG, Coughlin, C, Curran, WJ, Jr., et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys, 2011;81(3):623–30.
83.Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005;352(10):987–96.
84.Keime-Guibert, F, Chinot, O, Taillandier, L, Cartalat-Carel, S, Frenay, M, Kantor, G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med, 2007;356(15):1527–35.
85.Scott, J, Tsai, YY, Chinnaiyan, P, Yu, HH. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys, 2011;81(1):206–10.
86.Roa, W, Brasher, PM, Bauman, G, Anthes, M, Bruera, E, Chan, A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol, 2004;22(9):1583–8.
87.Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009;10(5):459–66.
88.Gallego Perez-Larraya, J, Ducray, F, Chinot, O, Catry-Thomas, I, Taillandier, L, Guillamo, JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol, 2011;29(22):3050–5.
89.Malmstrom, A, Gronberg, BH, Marosi, C, Stupp, R, Frappaz, D, Schultz, H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol, 2012;13(9):916–26.
90.Wick, W, Platten, M, Meisner, C, Felsberg, J, Tabatabai, G, Simon, M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol, 2012;13(7):707–15.
91.Combs, SE, Thilmann, C, Edler, L, Debus, J, Schulz-Ertner, D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol, 2005;23(34):8863–9.
92.Combs, SE, Widmer, V, Thilmann, C, Hof, H, Debus, J, Schulz-Ertner, D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer, 2005;104(10):2168–73.
93.Biswas, T, Okunieff, P, Schell, MC, Smudzin, T, Pilcher, WH, Bakos, RS, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol, 2009;4:11.
94.Sirin, S, Oysul, K, Surenkok, S, Sager, O, Dincoglan, F, Dirican, B, et al. Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: a single center experience. Vojnosanit Pregl, 2011;68(11):961–6.
95.Elliott, RE, Parker, EC, Rush, SC, Kalhorn, SP, Moshel, YA, Narayana, A, et al. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg, 2011;76(1–2):128–40; discussion 61–2.
96.Skeie, BS, Enger, PO, Brogger, J, Ganz, JC, Thorsen, F, Heggdal, JI, et al. Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg, 2012;78(6):658–69.
97.Larson, DA, Prados, M, Lamborn, KR, Smith, V, Sneed, PK, Chang, S, et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys, 2002;54(5):1397–404.
98.Minniti, G, Scaringi, C, De Sanctis, V, Lanzetta, G, Falco, T, Di Stefano, D, et al. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neuro-Oncol, 2013;111(2):187–94.
99.Gabayan, AJ, Green, SB, Sanan, A, Jenrette, J, Schultz, C, Papagikos, M, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery, 2006;58(4):701–9.
100.Chan, TA, Weingart, JD, Parisi, M, Hughes, MA, Olivi, A, Borzillary, S, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys, 2005;62(4):1133–9.